Introduction
Tumor relapse remains the major cause of morbidity and mortality in patients with hematologic malignancies receiving autologous hematopoietic stem cell transplantation (HSCT) for hematolymphoid rescue. According to CIBMTR, ~80% of mortality after autologous HSCT (2010-2011) resulted from relapse of primary disease or infection in patients with myeloma, lymphoma, and leukemia. 1 Multifaceted immunotherapeutic approaches combined with HSCT for patients with hematopoietic malignancy continue to hold large, but as yet unfulfilled promise. 2 Such enthusiasm for immune-based strategies rests in part from the notion that vaccination regimens can be employed early post-HSCT during 'reboot' of the immune system to promote efficient anti-tumor and antipathogen immunity by taking advantage of minimal residual disease as well as the lymphopenia present. [3] [4] [5] [6] [7] [8] [9] Nevertheless, generating successful protocols early post-HSCT must account for the relative dearth of T cells as well as the need for a vaccine with appropriate tumor or pathogen antigens to promote successful immunity.
Heat shock protein gp96 is the resident endoplasmic reticulum protein chaperone and is intimately involved in MHC-I restricted antigen presentation. [10] [11] [12] [13] [14] [15] [16] Following necrosis, gp96-peptide complexes are released and can be taken up by antigen presenting cells (APC) leading to peptide delivery and their efficient activation. 17, 18 These APC can therefore cross-present gp96-chaperoned peptides to CD8 + T lymphocytes,secreting tumor cell vaccine generated a CD8 + IFN-γ + response (allo-reactive), and these individuals exhibited prolonged survival compared to non-responders. 29 Notably, gp96-Ig vaccination also stimulated natural killer (NK) cells in anti-tumor models, and this population was hypothesized to contribute to CD8 + T cell expansion. Perforin-1 deficient mice (B6-Pfp −/− , PrfKO) were generated as described. BM transplantation. BM was isolated from femurs, tibias, and vertebral columns as described.
45,46
Briefly, T cells were removed by incubation with anti-CD90.2 (HO134), anti-CD4 (RL174), and anti-CD8 (H022) ascites (1:5) with 12% vol/vol Low-Tox M rabbit complement (Cedarlane Labs) at a final concentration of 25.0 x 10 6 cells/mL on ice for 15 min followed by 37 °C incubation for 30 min. B6 mice were conditioned with 9.5 Gy total body irradiation. The following day, 5.0 x 10 6 congenic B6-CD45.1 + T cell depleted (TCD)-BM cells were infused intravenously alone or together with the selected donor T cell populations (0.2 mL RPMI-1640). Mice were maintained briefly on gentamicin supplemented water.
Tumor cell inoculation into BM recipients or T cell donors. E.G7 and EL-4 lymphoma cells were isolated from log-phase cultures. One day following BM transplants, 1.0 x 10 5 or 5000 cells, respectively, were injected intraperitoneally (0.5 mL RPMI-1640). Tumor bearing T cell donor mice were inoculated intraperitoneally with 4.0 x 10 6 E.G7 cells 3 wk before T cell harvest. Some donor The number of bacteria injected was confirmed by growth on brain/heart infusion agar plates. Seven days post-infection, spleens were disrupted using 0.2 μ m screens in 0.05% Triton X-100 and CFU were determined by serial dilutions after incubation for 18 h at 37 °C on brain/heart infusion agar plates.
Statistical analysis. Paired comparisons performed using t test, multiple analyses performed using one-way or two-way ANOVA, and survival analyses performed using log-rank test; *: p ≤ 0.05, **: p ≤ 0.01, ***: p≤0.001, ****: p≤0.0001. post-vaccination), comprising ~90% of its entire cellularity ( Figure 1A) . Initially, these myeloid cells were of recipient origin, but were rapidly replaced by their donor counterparts over the course of the immune response (within days, data not shown). Interestingly, at 2 d post-vaccination, tumor-reactive CD8 + T lymphocytes could not be detected at the vaccine site ( Figure 1A) ; however, within 24 h, elevated levels were observed in the blood (data not shown) and maximum numbers were reached in the peritoneal cavity 5 d following a single vaccination ( Figure 1B) . At this time, large numbers of macrophages could still be enumerated, together with lower numbers of inflammatory monocytes ( Figure 1B) . Notably, vaccination with parental E.G7 cells containing endogenous gp96 did not induce these cellular responses ( Figure 1A-B) .
Syngeneic HSCT recipients vaccinated a second time (6 d following the first vaccination) with tumor cells secreting gp96-Ig contained similar numbers of tumor-reactive CD8 + T cells at the vaccine site as observed after a single vaccination, and elevated numbers of these cells were now detected in the spleen ( Figure 1C ). Proliferative signals engendered by lymphopenia diminish over time in myeloablatively conditioned mice. 8, 51 We found that vaccination could be delayed 1-2 wk post-HSCT and similar levels of tumor-reactive CD8 + T lymphocytes were observed at the vaccine site 5 d
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From following vaccination (Figure 1D) . CD8 + T cells introduced into a lymphopenic environment assume a central-memory phenotype (CD62L + CD44 + , Figure 1E ). HSCT, donor and recipient APC were both found to contribute to overall tumor-reactive CD8 + T lymphocyte expansion (Figure 2A) . Strikingly, when vaccination was delayed 1 wk post-HSCT, only donor APC contributed to the response, since such expansion was not observed when B7 deficient BM cells were transplanted into WT hosts ( Figure 2B ). To address the importance of crosspresentation by these donor APC, TCD-BM from Batf3 deficient mice (Batf3KO), which lack CD11c + CD8α + cross-presenting dendritic cells, 57,58 was used for transplantation ( Figure S1 ). These recipients were unable to expand tumor-reactive CD8 + T cells following gp96-Ig vaccination ( Figure   2C ). Our group reported that perforin-1 was required for tumor-reactive CD8 + T lymphocyte expansion induced by vaccination with tumor cells secreting gp96-Ig in non-transplanted mice.
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Using either donors or recipients deficient in perforin-1 (PrfKO), transplants determined that perforin-1 was also required in HSCT recipients, and interestingly, donor or recipient derived perforin-1 was sufficient to support this expansion ( Figure 2D ). To identify which donor leukocyte populations were required for augmented anti-tumor immunity following vaccine and IL-2 therapy (as in Figure 5 ), donor TCD-BM was supplemented with purified Table S1 ). The animals that were not protected following re-challenge (2/20) were greater than 1 y of age. Untreated, non-transplanted mice were also not protected (9/9, see Figure S9 ,left for kinetics of tumor growth and Figure   S9 ,right for recipient survival). Interestingly, recipients transplanted with purified CD8 + T cells (n = 2) also rejected this subcutaneous tumor challenge (data not shown).
Effectiveness of gp96-

Administration of directed IL-2 enhanced innate and adaptive immunity in the early post-HSCT
period. The vaccine site was analyzed following 3 treatments with IL-2 S4B6 (during the peak of the CD8 + T cell response, Figure 5A ) to address the effect of directed IL-2 on NK cells post-transplant. Clinical studies have demonstrated that tumor-specific CD8 + T cell responses can be elicited in myeloma patients within 1-2 mo following autologous HSCT. 63 Responses in these patients were generated employing multi-epitope predicted tumor antigen vaccines against hTERT and survivin. Figure 5F ). This time frame is prior to production and emigration of new thymic derived T cells, which takes place 2-3 wk post-HSCT. 70 Together with the observation that gp96-Ig vaccination alone or together with IL-2 S4B6 did not evoke protective immunity in recipients receiving TCD-BM grafts ( Figure   4C ) or purified CD4 + T cells ( Figure 6D ), respectively, we conclude that the vaccination regimens here expanded transplanted donor CD8 + T cells very early following HSCT, paralleling clinical findings requiring the addition of large numbers of T cells to provide detectable immunity.
65
Few pre-clinical studies have incorporated heat shock protein preparations into vaccine strategies for treating hematologic malignancies, including myeloma. 71, 72 In the context of experimental syngeneic HSCT, multiple vaccinations with purified autologous lymphoma derived gp96 resulted in increased survival in a model of minimal residual lymphoma. [73] [74] [75] In contrast to the present studies, 2-4 times the amount of gp96 was required, and the first vaccination was administered 2 wk post-HSCT, with subsequent vaccinations after the emergence of thymic derived T cells. Notably, in our immediate vaccination strategy, although recipient APC initially contributed to eliciting tumor-reactive CD8 + T cells (Figure 2A ), the response rapidly became singularly dependent on donor B7 expressing APC ( Figure 2B ), which included a critical CD11c + CD8α + cross-presenting DC population ( Figure 2C ), and required perforin-1 ( Figure 2D ). Therefore, enriched donor T cells plus CD34 + progenitors may not be optimal for use with this vaccine strategy. The role of perforin-1 remains obscure, but could involve NK-APC interactions early during the response.
76-78
The initial use of IL-2 in combination with vaccination or complexed to an anti-IL-2 mAb in the 1990s reported increased CD8 + T cell proliferation and enhanced anti-tumor immunity in vivo. 79 33 We detected virtually no change in CD4 + T cell and Treg levels ( Figure S2 ), indicating that under such conditions, IL-2 S4B6 complex most efficiently targeted transplanted donor CD8 + T cells.
For For For -infusion or (B-D) delayed infusion of (A-B,D) E.G7-gp96-Ig (tumor), ○ : E.G7-gp96-Ig (naive).
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